An early-career Cleveland Clinic researcher has devised a multipronged strategy that integrates advanced computational and experimental approaches to dementia research. The work has attracted $16 million in external grant funding in 2023 alone.Read More
The case launches the first human trial of a novel adenovirus-based therapy designed as a one-time injection to treat a common form of HCM.
Our latest Neuro Pathways podcast explores observed gender differences in PD and shares how we’re using a novel female-tailored patient questionnaire to better understand the disease in women.
Little is known about the genes that may influence Parkinson’s disease risk in Latinos, but a multinational research consortium is working to change that. Hear from the consortium’s U.S. coordinator in our latest podcast episode.
Sponsored genetic testing appears to be an attractive option for both patient and clinician, but experts say there are nonfinancial disadvantages that can create ethical challenges. Here’s what to know and how to counsel patients.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
The world’s first quantum computer devoted to healthcare research is now operational at Cleveland Clinic, part of a landmark partnership with IBM called the Discovery Accelerator that will use advanced computing technologies to hasten biomedical innovations.
Studying the relationship between autism spectrum disorder and cancer in individuals affected by PTEN hamartoma tumor syndrome is the subject of a new $2 million grant awarded from the National Institutes of Health to Charis Eng, MD, PhD, Chair of the Genomic Medicine Institute.
Application of the novel framework has identified the dyslipidemia medication gemfibrozil as a candidate drug to reduce Alzheimer’s disease risk.
A broad research effort involving network-medicine methodologies and pharmacoepidemiologic analysis has pinpointed the diabetes medication metformin as a leading antiarrhythmic candidate drug.
A combination of pharmacoepidemiologic studies and Mendelian randomization genetic analysis revealed preferential protection in Black but not white individuals. The findings support ongoing studies of telmisartan for Alzheimer’s, particularly in racially diverse cohorts.
While pharmacogenomic testing can flag patients at risk for events from drug-drug or drug-gene interactions, careful monitoring of patients’ drug regimens for potential interactions is an effective and often more feasible strategy.